サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1676226

多発性骨髄腫治療の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2025年から2033年までの予測

Global Multiple Myeloma Therapeutics Market Research Report- Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033

出版日
ページ情報
英文 107 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
多発性骨髄腫治療の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2025年から2033年までの予測
出版日: 2025年03月01日
発行: Value Market Research
ページ情報: 英文 107 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

多発性骨髄腫治療の世界市場規模は、2024年の329億6,000万米ドルから2033年には610億7,000万米ドルに成長し、2026～2033年の予測期間中に7.09％の堅調な年間平均成長率（CAGR）を示すと予測されます。

多発性骨髄腫治療市場は、多発性骨髄腫の罹患率の増加と治療選択肢の進歩に牽引され、力強い成長を遂げています。多発性骨髄腫は、骨髄における異常な形質細胞の増殖を特徴とする血液がんの一種であり、診断と管理の面で大きな課題を抱えています。医療プロバイダーが患者の予後を改善しようと努める中、モノクローナル抗体、プロテアソーム阻害剤、免疫調節薬などの革新的な治療に対する需要が急増しています。個別化医療や標的治療が重視されるようになったことで、臨床医は個々の患者のプロファイルに合わせた治療レジメンを目指しており、市場はさらに拡大しています。

技術的進歩は多発性骨髄腫治療市場の形成に極めて重要な役割を果たしており、ドラッグデリバリーシステムの革新は治療の有効性と安全性を高めています。CAR T細胞療法と二重特異性抗体の出現は、多発性骨髄腫治療における新たなフロンティアであり、再発または難治性の患者に有望な結果をもたらします。さらに、コンパニオン診断薬の統合により、医療プロバイダーは特定の治療が最も有効であると思われる患者を特定することができるようになり、それによって治療成績が最適化されます。市場が進化を続ける中、研究開発を優先して治療の提供を進める企業は、競合を獲得する可能性が高いです。

さらに、多発性骨髄腫治療市場は、規制の進展や新治療法の臨床的検証の必要性の影響をますます受けています。医療制度がエビデンスによる診療を採用するにつれ、厳密な臨床検査を通じて安全性と有効性を実証した治療に対する需要は増加の一途をたどると考えられます。この動向は、新規治療法の組み合わせの探索や既存治療法の改善を目的とした研究イニシアティブへの投資を促進しています。さらに、患者中心の治療への注目の高まりと、治療の決定におけるQOLの重要性が、多発性骨髄腫治療の状況を形成しています。製品開発を臨床ニーズと整合させ、患者の転帰を改善するソリューションの価値を実証する企業は、このダイナミックな市場で成功する好位置につけると考えられます。

当社のレポートは、様々な産業や市場に関する包括的かつ実用的な洞察をクライアントに提供するために綿密に作成されています。各レポートは、市場情勢を完全に理解するために、いくつかの重要な要素を含んでいます。

市場概要：市場概要：定義、分類、産業の現状を含む市場の詳細なイントロダクション。

市場促進要因：市場成長に影響を与える主要促進要因・抑制要因・市場促進要因・課題を詳細に分析します。このセクションでは、技術の進歩、規制の変更、新たな動向などの要因を検証します。

セグメンテーション分析：製品タイプ、用途、エンドユーザー、地域などの基準に基づき、市場を明確なセグメントに内訳。この分析により、各セグメントの業績と将来性を明らかにします。

競合情勢：市場シェア、製品ポートフォリオ、戦略的イニシアティブ、財務実績など、主要市場参入企業の包括的評価。主要企業が採用する競合力学と主要戦略に関する考察を記載しています。

市場予測：過去のデータと現在の市場状況に基づき、一定期間における市場規模と成長動向を予測。これには、定量的分析と将来の市場軌跡を示すグラフ表示が含まれます。

地域分析：地域による市場パフォーマンスを評価し、主要市場や地域動向を明らかにします。地域の市場力学とビジネス機会を理解するのに役立ちます。

新たな動向と機会：現在の市場動向と新たな市場動向、技術革新、潜在的な投資対象セグメントを特定します。将来の市場開拓と成長展望に関する洞察を記載しています。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 多発性骨髄腫治療産業分析

  • イントロダクション-市場力学
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 産業動向
  • ポーターのファイブフォース分析
  • 市場の魅力分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原料分析
    • 原料リスト
    • 原料メーカー一覧
    • 主要原料の価格動向
  • 潜在的バイヤーリスト
  • マーケティングチャネル
    • 直接マーケティング
    • 間接マーケティング
    • マーケティングチャネル発展動向

第5章 多発性骨髄腫治療の世界市場分析：治療タイプ別

  • 治療タイプ別概要
  • 治療タイプ別過去・予測データ分析
  • 化学療法
  • 標的療法
  • 免疫調節薬
  • 幹細胞移植
  • 放射線療法

第6章 多発性骨髄腫治療の世界市場分析：投与経路別

  • 投与経路別概要
  • 投与経路別過去・予測データ分析
  • 経口
  • 非経口

第7章 多発性骨髄腫治療の世界市場分析：疾患タイプ別

  • 疾患タイプ別概要
  • 疾患タイプ別過去・予測データ分析
  • 活動性多発性骨髄腫
  • くすぶり型多発性骨髄腫

第8章 多発性骨髄腫治療の世界市場分析：最終用途別

  • 最終用途別概要
  • 最終用途別過去・予測データ分析
  • 病院
  • 専門クリニック
  • 在宅医療
  • その他

第9章 多発性骨髄腫治療の世界市場分析：地域別

  • 地域別展望
  • イントロダクション
  • 北米売上分析
    • 概要、実績と予測
    • 北米：セグメント別
    • 北米：国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州売上分析
    • 概要、実績と予測
    • 欧州：セグメント別
    • 欧州：国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他の欧州
  • アジア太平洋売上分析
    • 概要、実績と予測
    • アジア太平洋：セグメント別
    • アジア太平洋：国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • 東南アジア
    • その他のアジア太平洋
  • ラテンアメリカ売上分析
    • 概要、実績と予測
    • ラテンアメリカ：セグメント別
    • ラテンアメリカ：国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他のラテンアメリカ
  • 中東・アフリカ売上分析
    • 概要、実績と予測
    • 中東・アフリカ：セグメント別
    • 中東・アフリカ：国別一覧
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他の中東・アフリカ

第10章 多発性骨髄腫治療企業の競合情勢

  • 多発性骨髄腫治療市場の競合
  • 提携/共同研究/契約
  • 合併・買収
  • 新製品の上市
  • その他の開発

第11章 企業プロファイル

  • 上位企業の市場シェア分析
  • 市場集中度
  • Cleveland Clinic
  • Dana-Farber Cancer Institute Inc.
  • Mayo Foundation For Medical Education And Research（MFMER）
  • MD Anderson Cancer Center
  • Memorial Sloan Kettering Cancer Center
  • AbbVie Inc. Amgen Inc.
  • Bristol-Myers Squibb Company
  • Glenmark Pharmaceuticals Ltd.
  • Johnson & Johnson Services Inc.
  • Merck & Co. Inc.
  • Novartis AG
  • Sanofi S.A
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Treatment Type (USD MN)
  • Chemotherapy Market Sales By Geography (USD MN)
  • Targeted Therapy Market Sales By Geography (USD MN)
  • Immunomodulating Agents Market Sales By Geography (USD MN)
  • Stem Cell Transplantation Market Sales By Geography (USD MN)
  • Radiation Therapy Market Sales By Geography (USD MN)
  • Analysis By Route Of Administration (USD MN)
  • Oral Market Sales By Geography (USD MN)
  • Parenteral Market Sales By Geography (USD MN)
  • Analysis By Disease Type (USD MN)
  • Active Multiple Myeloma Market Sales By Geography (USD MN)
  • Smoldering Multiple Myeloma Market Sales By Geography (USD MN)
  • Analysis By End-Use (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Specialty Clinics Market Sales By Geography (USD MN)
  • Homecare Settings Market Sales By Geography (USD MN)
  • Other Market Sales By Geography (USD MN)
  • Global Multiple Myeloma Therapeutics Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Multiple Myeloma Therapeutics Report
  • Market Research Process
  • Market Research Methodology
  • Global Multiple Myeloma Therapeutics Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Treatment Type
  • Market Attractiveness Analysis By Route Of Administration
  • Market Attractiveness Analysis By Disease Type
  • Market Attractiveness Analysis By End-Use
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Treatment Type (USD MN)
  • Chemotherapy Market Sales By Geography (USD MN)
  • Targeted Therapy Market Sales By Geography (USD MN)
  • Immunomodulating Agents Market Sales By Geography (USD MN)
  • Stem Cell Transplantation Market Sales By Geography (USD MN)
  • Radiation Therapy Market Sales By Geography (USD MN)
  • Global Market Analysis By Route Of Administration (USD MN)
  • Oral Market Sales By Geography (USD MN)
  • Parenteral Market Sales By Geography (USD MN)
  • Global Market Analysis By Disease Type (USD MN)
  • Active Multiple Myeloma Market Sales By Geography (USD MN)
  • Smoldering Multiple Myeloma Market Sales By Geography (USD MN)
  • Global Market Analysis By End-Use (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Specialty Clinics Market Sales By Geography (USD MN)
  • Homecare Settings Market Sales By Geography (USD MN)
  • Other Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis
  • Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.
目次
Product Code: VMR11216795

Global Multiple Myeloma Therapeutics Market size is anticipated to grow from USD 32.96 Billion in 2024 to USD 61.07 Billion by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 7.09% during the forecast period of 2026 to 2033.

The Multiple Myeloma Therapeutics market is experiencing robust growth, driven by the increasing incidence of multiple myeloma and the ongoing advancements in treatment options. Multiple myeloma, a type of blood cancer characterized by the proliferation of abnormal plasma cells in the bone marrow, presents significant challenges in terms of diagnosis and management. As healthcare providers seek to improve patient outcomes, the demand for innovative therapeutics, including monoclonal antibodies, proteasome inhibitors, and immunomodulatory drugs, is surging. The growing emphasis on personalized medicine and targeted therapies is further propelling the market, as clinicians aim to tailor treatment regimens to individual patient profiles.

Technological advancements are playing a pivotal role in shaping the Multiple Myeloma Therapeutics market, with innovations in drug development and delivery systems enhancing treatment efficacy and safety. The emergence of CAR T-cell therapy and bispecific antibodies represents a new frontier in multiple myeloma treatment, offering promising results for patients with relapsed or refractory disease. Additionally, the integration of companion diagnostics is enabling healthcare providers to identify patients who are most likely to benefit from specific therapies, thereby optimizing treatment outcomes. As the market continues to evolve, companies that prioritize research and development to advance their therapeutic offerings will likely gain a competitive edge.

Moreover, the Multiple Myeloma Therapeutics market is increasingly influenced by regulatory developments and the need for clinical validation of new therapies. As healthcare systems adopt evidence-based practices, the demand for therapeutics that demonstrate safety and efficacy through rigorous clinical trials will continue to rise. This trend is driving investment in research initiatives aimed at exploring novel treatment combinations and improving existing therapies. Furthermore, the growing focus on patient-centric care and the importance of quality of life in treatment decisions are shaping the landscape of multiple myeloma therapeutics. Companies that align their product development with clinical needs and demonstrate the value of their solutions in improving patient outcomes will be well-positioned to thrive in this dynamic market.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

SEGMENTATION COVERED IN THE REPORT

By Treatment Type

  • Chemotherapy
  • Targeted Therapy
  • Immunomodulating Agents
  • Stem Cell Transplantation
  • Radiation Therapy

By Route Of Administration

  • Oral
  • Parenteral

By Disease Type

  • Active Multiple Myeloma
  • Smoldering Multiple Myeloma

By End-Use

  • Hospitals
  • Specialty Clinics
  • Homecare Settings
  • Other
  • COMPANIES PROFILED
  • Cleveland Clinic
  • Dana-Farber Cancer Institute Inc.
  • Mayo Foundation for Medical Education and Research (MFMER)
  • MD Anderson Cancer Center
  • Memorial Sloan Kettering Cancer Center
  • AbbVie Inc. Amgen Inc.
  • Bristol-Myers Squibb Company
  • Glenmark Pharmaceuticals Ltd.
  • Johnson & Johnson Services Inc.
  • Merck & Co. Inc.
  • Novartis AG
  • Sanofi S.A.
  • The above list can be customized.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. MULTIPLE MYELOMA THERAPEUTICS INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porters Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Treatment Type
    • 3.7.2 Market Attractiveness Analysis By Route Of Administration
    • 3.7.3 Market Attractiveness Analysis By Disease Type
    • 3.7.4 Market Attractiveness Analysis By End-Use
    • 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET ANALYSIS BY TREATMENT TYPE

  • 5.1. Overview By Treatment Type
  • 5.2. Historical and Forecast Data Analysis By Treatment Type
  • 5.3. Chemotherapy Historic and Forecast Sales By Regions
  • 5.4. Targeted Therapy Historic and Forecast Sales By Regions
  • 5.5. Immunomodulating Agents Historic and Forecast Sales By Regions
  • 5.6. Stem Cell Transplantation Historic and Forecast Sales By Regions
  • 5.7. Radiation Therapy Historic and Forecast Sales By Regions

6. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

  • 6.1. Overview By Route Of Administration
  • 6.2. Historical and Forecast Data Analysis By Route Of Administration
  • 6.3. Oral Historic and Forecast Sales By Regions
  • 6.4. Parenteral Historic and Forecast Sales By Regions

7. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET ANALYSIS BY DISEASE TYPE

  • 7.1. Overview By Disease Type
  • 7.2. Historical and Forecast Data Analysis By Disease Type
  • 7.3. Active Multiple Myeloma Historic and Forecast Sales By Regions
  • 7.4. Smoldering Multiple Myeloma Historic and Forecast Sales By Regions

8. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET ANALYSIS BY END-USE

  • 8.1. Overview By End-Use
  • 8.2. Historical and Forecast Data Analysis By End-Use
  • 8.3. Hospitals Historic and Forecast Sales By Regions
  • 8.4. Specialty Clinics Historic and Forecast Sales By Regions
  • 8.5. Homecare Settings Historic and Forecast Sales By Regions
  • 8.6. Other Historic and Forecast Sales By Regions

9. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook
  • 9.2. Introduction
  • 9.3. North America Sales Analysis
    • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.3.2 North America By Segment Sales Analysis
    • 9.3.3 North America By Country Sales Analysis
    • 9.3.4 United States Sales Analysis
    • 9.3.5 Canada Sales Analysis
    • 9.3.6 Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.4.2 Europe By Segment Sales Analysis
    • 9.4.3 Europe By Country Sales Analysis
    • 9.4.4 United Kingdom Sales Analysis
    • 9.4.5 France Sales Analysis
    • 9.4.6 Germany Sales Analysis
    • 9.4.7 Italy Sales Analysis
    • 9.4.8 Russia Sales Analysis
    • 9.4.9 Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.5.2 Asia Pacific By Segment Sales Analysis
    • 9.5.3 Asia Pacific By Country Sales Analysis
    • 9.5.4 China Sales Analysis
    • 9.5.5 India Sales Analysis
    • 9.5.6 Japan Sales Analysis
    • 9.5.7 South Korea Sales Analysis
    • 9.5.8 Australia Sales Analysis
    • 9.5.9 South East Asia Sales Analysis
    • 9.5.10 Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.6.2 Latin America By Segment Sales Analysis
    • 9.6.3 Latin America By Country Sales Analysis
    • 9.6.4 Brazil Sales Analysis
    • 9.6.5 Argentina Sales Analysis
    • 9.6.6 Peru Sales Analysis
    • 9.6.7 Chile Sales Analysis
    • 9.6.8 Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.7.2 Middle East & Africa By Segment Sales Analysis
    • 9.7.3 Middle East & Africa By Country Sales Analysis
    • 9.7.4 Saudi Arabia Sales Analysis
    • 9.7.5 UAE Sales Analysis
    • 9.7.6 Israel Sales Analysis
    • 9.7.7 South Africa Sales Analysis
    • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE MULTIPLE MYELOMA THERAPEUTICS COMPANIES

  • 10.1. Multiple Myeloma Therapeutics Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11. COMPANY PROFILES OF MULTIPLE MYELOMA THERAPEUTICS INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. Cleveland Clinic
    • 11.3.1 Company Overview
    • 11.3.2 Company Revenue
    • 11.3.3 Products
    • 11.3.4 Recent Developments
  • 11.4. Dana-Farber Cancer Institute Inc.
    • 11.4.1 Company Overview
    • 11.4.2 Company Revenue
    • 11.4.3 Products
    • 11.4.4 Recent Developments
  • 11.5. Mayo Foundation For Medical Education And Research (MFMER)
    • 11.5.1 Company Overview
    • 11.5.2 Company Revenue
    • 11.5.3 Products
    • 11.5.4 Recent Developments
  • 11.6. MD Anderson Cancer Center
    • 11.6.1 Company Overview
    • 11.6.2 Company Revenue
    • 11.6.3 Products
    • 11.6.4 Recent Developments
  • 11.7. Memorial Sloan Kettering Cancer Center
    • 11.7.1 Company Overview
    • 11.7.2 Company Revenue
    • 11.7.3 Products
    • 11.7.4 Recent Developments
  • 11.8. AbbVie Inc. Amgen Inc.
    • 11.8.1 Company Overview
    • 11.8.2 Company Revenue
    • 11.8.3 Products
    • 11.8.4 Recent Developments
  • 11.9. Bristol-Myers Squibb Company
    • 11.9.1 Company Overview
    • 11.9.2 Company Revenue
    • 11.9.3 Products
    • 11.9.4 Recent Developments
  • 11.10. Glenmark Pharmaceuticals Ltd.
    • 11.10.1 Company Overview
    • 11.10.2 Company Revenue
    • 11.10.3 Products
    • 11.10.4 Recent Developments
  • 11.11. Johnson & Johnson Services Inc.
    • 11.11.1 Company Overview
    • 11.11.2 Company Revenue
    • 11.11.3 Products
    • 11.11.4 Recent Developments
  • 11.12. Merck & Co. Inc.
    • 11.12.1 Company Overview
    • 11.12.2 Company Revenue
    • 11.12.3 Products
    • 11.12.4 Recent Developments
  • 11.13. Novartis AG
    • 11.13.1 Company Overview
    • 11.13.2 Company Revenue
    • 11.13.3 Products
    • 11.13.4 Recent Developments
  • 11.14. Sanofi S.A
    • 11.14.1 Company Overview
    • 11.14.2 Company Revenue
    • 11.14.3 Products
    • 11.14.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies